Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
株式のランク #32324
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
株価
$0.88
最終同期: 2026-08-17
時価総額
$10.41M
変化(1日)
-7.26%
変化(1年)
-50.56%
SG
取引 CytoMed Therapeutics Limited (GDTC)

カテゴリー

CytoMed Therapeutics Limited(GDTC)の発行済株式数
August 2026 時点の発行済株式数 0
CytoMed Therapeutics Limited の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
CytoMed Therapeutics Limited(GDTC)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
- -
KR